Sonendo Inc Secures $5M Funding Round to Accelerate GentleWave System Growth

Sonendo Inc (OTC PINK: SONX) has closed a $5.0 million private placement that signals growing investor confidence in its dental innovation platform. The funding round saw participation from both new investors and existing shareholders, including members of the company’s board and executive team—a strong vote of confidence in leadership.

Capital Raising Details

The dental technology company issued 4,000,000 shares at $1.25 per share, representing approximately a 10% premium to the recent market closing price. Brookline Capital Markets acted as the placement agent for the round. This valuation uplift suggests investors see meaningful upside potential in Sonendo’s restructuring efforts and revenue stabilization trajectory.

Strategic Use of Proceeds

Sonendo plans to deploy the capital across several key priorities: expanding commercial programs to drive revenue acceleration, continuing business restructuring initiatives to cut operating expenses further, and working toward positive adjusted EBITDA. The company is also earmarking funds to retain senior leadership and retain key talent—critical for executing its turnaround strategy.

Credit Facility Amendments Support Path Forward

In parallel, Sonendo secured two amendments to its credit agreement with Perceptive Credit Holdings III, LP. The amendments reduced minimum gross proceed requirements for future equity raises and provided meaningful relief through payment deferrals. Amortization payments due in February and March 2025 were waived, while payments from April 30, 2025 through March 2026 are deferred—improving near-term cash flow dynamics considerably.

CEO Bjarne Bergheim noted: “Our lender and investors recognize the operational progress we’ve made. We’ve stabilized revenue, significantly reduced cash burn, and improved our cost structure. This capital raise and credit facility amendments substantially strengthen our liquidity position heading into 2025.”

The GentleWave Edge

Sonendo’s core product, the GentleWave System, addresses tooth decay—the most common chronic disease globally. Unlike traditional root canal therapy, the system uses acoustic energy and advanced fluid dynamics to clean and disinfect root canal systems while preserving tooth structure. Clinical benefits include superior cleaning outcomes, faster healing, minimal post-operative pain, and improved economics for dental practices.

The company expects continued gross margin expansion and reduced operating losses throughout 2025 as commercial traction builds.